Building Better Oral Suspensions for Pediatric & Real-World Use
February 18, 2026
Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation
4 min read
False
February 18, 2026
Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation
4 min read
February 17, 2026
Phase 3 results show fenebrutinib matched OCREVUS on disability progression in PPMS
2 min read
By Dan Williams
February 6, 2026
AI, data-sharing, and gene technologies are peering into the future of rare disease drug development, and overcoming economic, regulatory, and diagnostic challenges for transformative therapies.
9 min read
By Chris Moore
February 5, 2026
Why people, process, and purpose matter most
5 min read
By Jennifer Cannon
February 3, 2026
The next era of drug development will be connected, data-driven and centered on patient impact
4 min read
January 15, 2026
About the Pediatric Praziquantel Consortium, and why a child-friendly treatment for preschool-aged children with schistosomiasis was needed
13 min read
By HH Kim
January 8, 2026
A billion-dollar acquisition, breakthrough clinical data, and a shifting scientific paradigm are pushing MASH out of the shadows and into a new era of metabolic medicine.
3 min read
December 22, 2025
The pandemic catalyzed a transformation in antiviral R&D. From better data to open collaboration, Tetiana Matviyuk of Enamine describes how the landscape has evolved.
3 min read
By Lisa Stehno-Bittel
December 8, 2025
Drug delivery innovation lags behind molecule discovery. Smarter polymer-based excipients can boost biologic stability, efficacy, and accessibility, transforming patient outcomes and biotech success.
3 min read
By Stephanie Vine
December 3, 2025
“For those of you who are removed from direct interaction with the patients…please remember that your work really matters. It is making a huge difference to human lives.”
3 min read
False
False
False